Lunit and Agilent Technologies Announce Collaboration to Enhance Development of Companion Diagnostic Solutions Powered with AI for Precision Medicine

Rhea-AI Summary

Agilent Technologies (NYSE: A) has announced a nonexclusive collaboration with Lunit (KRX:328130.KQ) to develop AI-powered companion diagnostic solutions. The partnership combines Lunit's artificial intelligence expertise with Agilent's tissue-based diagnostic capabilities to enhance biomarker testing accuracy.

The collaboration will initially focus on developing AI-powered assays for research and clinical trials, integrating Lunit's AI algorithms with Agilent's state-of-the-art assays. The joint solutions aim to support pharmaceutical companies in companion diagnostic product development, potentially accelerating the development of biomarker-driven therapies and improving patient treatment precision.

Positive

• Strategic partnership combines Agilent's diagnostic leadership with Lunit's AI expertise
• Potential to accelerate biomarker-driven therapy development
• Access to Lunit's established presence in over 7,000 medical institutions across 65 countries
• Enhancement of diagnostic accuracy through AI integration

Negative

• Nonexclusive nature of the collaboration may limit competitive advantages
• Initial focus limited to research and clinical trials phase

Insights

Healthcare Technology Analyst

Agilent's partnership with Lunit combines diagnostic expertise with AI to advance precision medicine and potentially accelerate revenue growth.

Agilent Technologies has entered a strategic nonexclusive collaboration with Lunit to develop AI-powered companion diagnostic (CDx) solutions that could significantly strengthen its position in the precision medicine market. This partnership intelligently combines Agilent's established leadership in tissue-based diagnostics with Lunit's specialized AI algorithms designed for cancer detection and analysis.

The collaboration addresses a critical market need: while biomarker testing forms the foundation of precision oncology, current processes remain heavily dependent on manual interpretation, creating inefficiencies and potential inconsistencies. By integrating AI capabilities into diagnostic workflows, the partnership aims to enhance the accuracy, precision, and speed of biomarker testing – three metrics that directly impact pharmaceutical development timelines and treatment efficacy.

For Agilent specifically, this collaboration represents a meaningful competitive enhancement to its Clinical Diagnostics Division. The company gains access to Lunit's AI expertise without exclusive commitments, allowing flexibility in future partnerships while immediately strengthening its offering to pharmaceutical partners developing biomarker-driven therapies.

The initial focus on research and clinical trial applications creates a clear commercialization pathway, as successful validation in these settings typically precedes broader clinical adoption. This methodical approach aligns with regulatory requirements while potentially accelerating Agilent's revenue growth in the expanding companion diagnostics market, which is projected to grow substantially as precision medicine becomes increasingly central to cancer treatment protocols.

Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities

SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, and Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics, and applied chemical markets, today announced a nonexclusive collaboration to develop AI-based companion diagnostic solutions. The collaboration will leverage Lunit's AI technology and Agilent's expertise in tissue-based companion diagnostics to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development.

Under this agreement, Lunit and Agilent will develop advanced AI-powered companion diagnostic tools designed to enhance the accuracy of diagnosis and the measurement of therapeutic efficacy. The initial focus will be on leveraging Lunit's AI algorithms with Agilent's state-of-the-art assays to evaluate biomarkers critical for the development of new pharmaceutical therapies.

The joint solutions will support pharmaceutical companies in companion diagnostic (CDx) product development, improving the precision and accuracy of biomarker testing, and ultimately benefiting patients with more tailored treatment options.

"Biomarker testing is at the heart of precision oncology, but today it is still largely dependent on manual interpretation," said Brandon Suh, CEO of Lunit. "By combining Agilent's global leadership in tissue-based diagnostics with Lunit's proven AI algorithms, we can help pharma partners bring biomarker-driven therapies to market faster and with greater confidence - ultimately ensuring patients receive the right treatment at the right time."

"Agilent is committed to bringing cutting-edge diagnostic solutions to our pharmaceutical partners and ultimately to patients, and this collaboration with Lunit further strengthens our ability to offer the most advanced companion diagnostic solutions available today," said Nina Green, vice-president and general manager of Agilent's Clinical Diagnostics Division at Agilent. "Through this collaboration with Lunit, we aim to deliver next-generation diagnostic tools that enable the advancement of precision medicine worldwide."

The collaboration will initially focus on the co-development of AI-powered assays for use in research and clinical trials. This agreement marks a significant step forward for both companies as they seek to redefine the role of artificial intelligence in precision oncology and translational medicine.

About Lunit

Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 7,000 medical institutions in more than 65 countries, while Lunit SCOPE is used in research partnerships with global pharma giants focused on biomarker development and companion diagnostics. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology—and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.

View original content to download multimedia:https://www.prnewswire.com/news-releases/lunit-and-agilent-technologies-announce-collaboration-to-enhance-development-of-companion-diagnostic-solutions-powered-with-ai-for-precision-medicine-302562617.html

SOURCE Lunit

FAQ

What is the purpose of Agilent and Lunit's AI collaboration announced in September 2025?

The collaboration aims to develop AI-powered companion diagnostic solutions that combine Lunit's AI technology with Agilent's tissue-based diagnostics expertise to enhance biomarker testing accuracy and support pharmaceutical development.

How will the Agilent-Lunit partnership benefit patients?

The partnership aims to ensure patients receive more precise treatments by improving biomarker testing accuracy and enabling more tailored treatment options through AI-powered diagnostic solutions.

What is Lunit's current market presence in medical diagnostics?

Lunit's FDA-cleared INSIGHT suite is currently used in over 7,000 medical institutions across more than 65 countries for cancer screening.

What is the initial focus of the Agilent-Lunit collaboration?

The collaboration will initially focus on co-developing AI-powered assays for use in research and clinical trials, leveraging Lunit's AI algorithms with Agilent's assays to evaluate critical biomarkers.

How does this collaboration affect Agilent's (NYSE: A) diagnostic capabilities?

The partnership strengthens Agilent's diagnostic capabilities by incorporating Lunit's AI technology into their existing tissue-based diagnostic solutions, enabling more advanced companion diagnostic tools.